|
|
 |
您现在的位置:产品中心 >>
分子生化试剂 >> 生化试剂 |
Bosutinib, Free Base
产品编号: |
B-1709-2 g
查看说明书 |
产品名称:
|
Bosutinib, Free Base .0 订购此产品 |
供应商:
|
LC |
规格: |
2 g |
目录价: |
35284 |
库存状态: |
|
CAS编号:
|
[380843-75-4] |
应用范围: |
|
种属来源: |
|
相关信息: |
|
B-1709 Explanation of the Bosutinib Problem and Bosutinib Isomer 1
•Bosutinib (SKI-606) is a tyrosine kinase inhibitor, more potent than imatinib. It has reached Phase II clinical trials in humans as an anti-cancer agent.
•Aside from the ongoing clinical studies, bosutinib is also used extensively in biomedical research laboratories around the world, for non-human, non-veterinary studies.
•Very unfortunately, an incorrect isomer of bosutinib has been sold to laboratory researchers under the name "Bosutinib" by 17 vendors, for various periods as long as several years. For extensive information about this bosutinib problem, please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html.
•LC Laboratories is one of the 17 vendors that sold the incorrect bosutinib isomer under the name "Bosutinib", and the corresponding catalog number was B-1709.
•To avoid confusion, we have permanently discontinued use of the B-1709 catalog number. All of the incorrect bosutinb isomer sold by LC Labs at any time was sold under the catalog number "B-1709" and name "Bosutinib, Free Base".
•We have now produced our own correct bosutinib and unambiguously proven its structure by X-ray crystallography. We have assigned a new catalog number, B-1788, to this correct bosutinib product. Please see that product page for extensive information, sizes and prices -- Cat. No. B-1788, Bosutinib, Free Base.
•We now refer to the particular incorrect bosutinib isomer erroneously sold by the 17 vendors as "Bosutinib Isomer 1".
•We have obtained unambiguous proof of the structure of Bosutinib Isomer 1 via X-ray crystallography, and we now offer this compound for sale under catalog number B-1722. Please see that product page for further information, sizes and prices -- Cat. No. B-1722, Bosutinib Isomer 1, Free Base.
•An 18th vendor has also sold incorrect bosutinib, specifically to the laboratory headed by Prof. Stefan Knapp. The incorrect version of bosutinib sold by this vendor has been unambiguously proven to be different from bosutinib but its actual structure has not yet been established.
|
保存条件: |
|
说明书地址: |
点击查看详细 |
|
|
打印此页 关闭此页 |
上一个:Bosutinib, Free Base[B-1709-100 mg/100 mg]
下一个:Bosutinib, Free Base[B-1709-200 mg/200 mg]
|
|
 |
 |
|